Family members of young adults admitted to or discharged from AHE, RAH, UAH, and hospitals in Covenant Health, Edmonton Zone, with diagnosis of psychosis (all causes) are recruited to attend an educational program delivered in two hour modules once a week for nine consecutive weeks. The curriculum delivers basic knowledge about psychosis and imparts evidence based skills to family members to effectively support their loved ones. Study results will be used to demonstrate to healthcare services and policy makers that integration of family centred care is possible in the context of serving young adults living with psychosis, is cost effective and leads to better outcomes both patients as well as their supporting families long term.

We are looking for people living in rural communities who are experiencing problems due to their gambling to participate in a research study. This study investigates the effects of providing small incentives for evidence of treatment success. Participants will be randomly allocated to either regular counselling or regular counselling and small incentives. All participants will receive free individual counselling from an experienced counsellor/therapist. The counselling is delivered on-line. Participants will be asked to complete a range of assessments. Compensation is provided.

COVID-19 has had a significant impact on the lives of many Albertans. Neurological deficits are an increasingly recognized complication of COVID-19, caused by the coronavirus, SARS-CoV-2. Among COVID-19 survivors, 10-30% develop persistent multi-system symptoms termed Long COVID. Neurocognitive impairments are commonly (>25%) reported in Long COVID, together with pain, fatigue and sleep disorders. Thus, the purpose of this study is to investigate if there are inflammatory causes of these neurocognitive symptoms as well as what is the prevalence, risk factors, and predictors of neurocognitive impairments among people with long COVID

The purpose of this study is to demonstrate how well the study treatment works and evaluate the safety, and how well you can tolerate any unwanted side effects caused by the study treatment, mavorixafor, in combination with any background therapy being received. Mavorixafor, has been shown in other clinical studies to increase a patient’s white blood cells, including their neutrophils.  Increasing neutrophils in a participant's blood is expected to help their body fight infection. An increase in neutrophils in the blood may not cause any symptoms and can only be observed with blood tests. Mavorixafor, is an investigative drug that has not yet been approved by the regulatory authorities in Canada for the indication in this study.

The Canadian Registry for Amyloidosis Research (CRAR) will serve to connect Canadian patients with physicians and researchers. Participation in the CRAR will help researchers to develop projects and learn more about amyloidosis and enable patients to be kept informed about upcoming research opportunities.

The balance between energy intake through food and energy expenditure through physical activity is essential for maintaining a healthy body weight and preventing diseases. Being able to self-monitor metabolic energy levels such as glucose, ketone, or lactate may encourage healthy choices; however, the current methods of measurements involve painful finger prick and costly consumables. We have designed a non-invasive metabolic energy monitoring sensor that can measure various metabolites in the body. In this study, we aim to create AI algorithms that will allow the sensors to accurately predict levels of various metabolites to help develop a novel wearable technology for health and wellness in the future.

Patients with permanent Bells palsy or facial nerve injury may be unable to blink and protect their cornea. Irreversible visual loss can occur if the cornea is not kept lubricated. Current treatment options for patients whose eyelid blink does not blink include frequent drops and ointment, patching the eye closed, sewing parts of the eyelid together (tarsorrpahy), upper lid gold weight, or a dental wire spring. As a more convenient option to the above alternatives, we propose a new spring to close the eyelid made out of the surgical stitches (sutures) commonly used in medicine and eyelid surgery. The stitch will be made into a custom shape and attached underneath the skin near the centre of the lid.

We are looking at individuals with a rare gene problem that causes their kidneys to pee out excessive phosphate. The gene is called SLC34A3 and it controls how the kidney handles phosphate, an important component of bone. This can lead to bone problems like early arthritis, and this can lead to kidney problems like kidney stones. We want to understand more about this condition and how it affects people.

This study is to assess the safety, tolerability and clinical efficacy of an investigational islet cell infusion, called VX-880. This study consists of a screening visit up to 60 days before receiving the infusion and a procedure to infuse the investigational treatment. You will need to attend follow-up visits monthly after the infusion for the first year and about every three months after for approximately five years. You will also receive several medicines before, during, and after the infusion of the islet cells and will be asked to take medicines for the entire duration of the study. You will be monitored throughout the study using continuous glucose monitor, which will be provided to you.

The study drug REGV131-LNP1265 is being developed to overcome the limitations of current gene therapies by inserting a functional F9 sequence into the albumin gene in liver cells. This treatment will prevent bleeding by restoring the production of functional Factor IX (9) activity to normal or near normal levels, eliminating the need for FIX replacement. The effects of REGV131-LNP1265 are intended to be irreversible and lifelong. In other words, this treatment is meant to be a cure for hemophilia B.